Introduction {#sec1}
============

Diabetic nephropathy (DN) is one of the most devastating complications of diabetes mellitus and is characterized by macroalbuminuria, hypertension, and decreased glomerular filtration rate (GFR) \[[@B1]\]. Recently, DN has become an important cause of mortality in patients with diabetes mellitus. There is a cause link between glucose control and the development of DN in diabetes patients. In addition, effective control of glucose leads to an obvious reduction in the risk of albuminuria of DN \[[@B2],[@B3]\]. However, little is known about the molecular pathogenesis of DN.

Carbohydrate response element binding protein (ChREBP) is a basic helix--loop--helix leucine zipper transcription factor that primarily mediates glucose homeostasis in the body. After forming a heterodimeric complex in the nucleus, this protein activates carbohydrate response element motifs for transcriptional regulation of its target genes in a glucose-dependent manner \[[@B4],[@B5]\]. Amounting evidence shows that ChREBP and its targets genes play critical roles in a wide range of physiological and pathological processes in the body \[[@B6]\]. In the liver, the production and transcriptional activity of ChREBP are controlled by fasting and feeding \[[@B7]\]. Moreover, the expression of ChREBP is markedly elevated in the liver of diabetic mice \[[@B8]\]. Conversely, knockdown of ChREBP in obese mice causes obvious metabolic disorders, such as glucose intolerance, insulin resistance, and liver steatosis \[[@B9]\].

In the present study, we detected the expression levels of ChREBP and its target genes in patients with type II diabetes and further investigated the roles of ChREBP in glomerular mesangial cells.

Materials and methods {#sec2}
=====================

Patients and tissue specimens {#sec2-1}
-----------------------------

Patients (62 cases) with type 2 diabetes mellitus (T2DM) were recruited in the Second Hospital of Jilin University from March 2015 to November 2017. Diagnostic criteria: meeting the 1999 WHO diagnosis of diabetes (fasting plasma glucose ≥ 7.0 mmol/l and/or 2-h postprandial plasma glucose ≥ 11.1 mmol/l) and the classification criteria, with kidney dysfunction to various degree. According to the 24 h-urinary albumin excretion rate (24 h-UAER), patients were divided to type 2 diabetes mellitus group (DM group, 24 h-UAER \< 30 mg/24 h) and diabetic nephropathy group (DN group, 24 h-UAER ≥ 30 mg/24 h). Thirty cases healthy subjects (NC group) without family history of diabetes were enrolled in the hospital within the same period. The blood samples were collected from the cubital vein, and the serum was isolated from the whole blood sample post coagulation. The present study was approved by the Internal Review Board (IRB) of Second Hospital of Jilin University, and each participant signed the informed consent.

Cell culture {#sec2-2}
------------

Renal mesangial SV40-MES 13 cells were obtained from American Type Culture Collection (ATCC) (Rockville, MD, U.S.A.) and were cultured in low glucose Dulbecco's Modified Eagle's Medium (DMEM; GIBCO, Rockville, MD, U.S.A.), supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, U.S.A.). The cells were incubated at 37°C, with 5% CO~2~.

Animals {#sec2-3}
-------

Male C57BL/6 mice were purchased from the Shanghai Laboratory Animal Company (SLAC, Shanghai, China). Mice were fasted for 4 h and injected intraperitoneally with 60 mg/kg STZ (Sigma-Aldrich, St. Louis, MO, U.S.A.) or vehicle control for five consecutive days. All animal experiments were approved by the Animal Ethics Committee of Jilin University.

Real-time PCR {#sec2-4}
-------------

RNA was isolated from cultured cells using the RNeasy mini-kit (Qiagen, Germany). The quantity and quality of total RNA samples were checked by Bioanalyzer RNA 6000 Nano assay (Agilent, Waldbronn, Germany). Total RNA (1 µg) was reverse transcribed into cDNA with the PrimeScript RT Master Mix Perfect Real Time (TaKaRa). Real-time PCR conditions were 25--30 cycles at 95°C for 30s, 56°C for 30s, and 72°C for 1 min. All reactions were performed in triplicate. The relative amounts of mRNA were calculated by using the comparative *C*~T~ method.

ELISA {#sec2-5}
-----

The production of ChREBP and inflammatory cytokines including TNF-α, IL-1β, and IL-6 was determined using a commercially available ELISA kit (R&D System, Minneapolis, Minn, U.S.A.). These concentrations were interpolated from the standard curves and all the samples were assayed in triplicate.

Western blot {#sec2-6}
------------

Whole cells were lysed in 1× SDS sample buffer and resolved by electrophoresis using SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with primary antibodies overnight, and then incubated with appropriate horseradish peroxide-conjugated secondary antibodies for 3 h followed by detection with a Super Signal Enhanced Chemiluminescence kit (Pierce, Rockford, IL). For sequential blotting, the membranes were stripped with Stripping Buffer (Pierce) and re-probed with proper antibodies.

Statistical analysis {#sec2-7}
--------------------

The results were calculated as the mean ± the standard derivation (SD). Significances between groups were evaluated using Student's *t*-test and one-way ANOVA. Values with *P*\<0.05 were considered statistically significant.

Results {#sec3}
=======

Clinical and biochemical characteristics {#sec3-1}
----------------------------------------

Main metabolic and biochemical characteristics of all subjects are summarized in [Table 1](#T1){ref-type="table"}. There were 13 males and 19 females with an average age of 54.59 ± 13.63 years in the DM group, and 12 males and 18 females with an average age of 52.70 ± 8.12 years in the DN group; and 10 males and 20 females were included in the control group with well-matched age of 51.07 ± 6.87 (*P*=0.390). The detailed values of BMI, FPG, HbA1c, TC, TG, HDL-C, LDL-C, FINS, Scr, or HOMA-IR in the DM, DN, or control group were shown in [Table 1](#T1){ref-type="table"}.

###### General characteristics of patients and healthy controls

  Parameters                NC (*n*=30)      DM (*n*=32)       DN (*n*=30)       *χ*^2^/*F/t*   *P*
  ------------------------- ---------------- ----------------- ----------------- -------------- ---------
  Age                       51.07± 6.87      54.59 ± 13.63     52.70 ± 8.12      0.951          0.390
  Male/female               10/20            13/19             12/18             0.422          0.810
  BMI (kg/m^2^)             21.88 ± 2.49     25.78 ± 3.60      25.99 ± 3.11      16.739         \<0.001
  FPG (mmol/l)              5.59 ± 0.29      9.84 ± 3.27       11.03 ± 3.27      34.626         \<0.001
  HbA1c (%)                 5.26 ± 0.35      8.57 ±1.96        9.85 ± 2.04       61.639         \<0.001
  FINS (mU/l)               8.69 ± 1.40      15.89 ± 10.18     18.50 ± 10.49     10.700         \<0.001
  HOMA-IR                   2.16 ± 0.38      6.83 ± 5.51       8.95 ± 6.27       15.462         \<0.001
  Scr (μmol/l)              53.57 ± 5.61     71.22 ± 25.13     73.30 ± 25.81     7.943          0.001
  TG (mmol/l)               0.77 ± 0.29      2.53 ± 1.60       3.21 ± 1.69       25.788         \<0.001
  TC (mmol/l)               2.94 ± 0.30      5.27 ± 1.33       6.46 ± 1.37       76.537         \<0.001
  HDL-C (mmol/l)            1.23 ± 0.12      1.21 ± 0.22       1.22 ± 0.21       0.091          0.913
  LDL-C (mmol/l)            2.71 ± 0.78      2.82 ± 0.22       2.79 ± 0.26       0.445          0.642
  24 h-UAER (mg/24 h)       17.78 ± 3.19     219.72 ± 183.12   222.10 ± 189.34   17.858         \<0.001
  eGFR (ml/min/1.73 m^2^)   130.75 ± 15.07   96.79 ± 37.43     92.73 ± 50.04     9.562          \<0.001
  IL-1β (pg/ml)             42.20 ± 6.79     64.30 ± 11.49     65.05 ± 10.59     52.327         \<0.001
  IL-6 (pg/ml)              44.11 ± 11.72    54.61 ± 6.21      55.32 ± 6.08      16.972         \<0.001
  ChREBP (ng/ml)            128.82 ± 22.85   153.81 ± 37.57    154.87 ± 37.17    5.922          0.004
  TNF-α (pg/ml)             41.49 ± 7.32     49.73 ± 6.70      51.49 ± 7.12      18.100         \<0.001

Serum ChREBP was up-regulated in T2DM patients and was correlated with pro-inflammatory cytokines {#sec3-2}
-------------------------------------------------------------------------------------------------

To investigate the inflammatory reaction to the high glucose in T2DM subjects, we then examined the serum levels of pre-inflammatory cytokines, such as TNFα, IL-1β, and IL-6, in T2DM patients and in control subjects. It was demonstrated that the serum levels of TNFα, IL-1β, and IL-6 were up-regulated in T2DM patients, compared with the control subjects (*P*\<0.05) ([Figure 1](#F1){ref-type="fig"}A--C). ChREBP was also increased in T2DM patients, compared with the control subjects (*P*\<0.05) ([Figure 1](#F1){ref-type="fig"}D). Additionally, there was a positive correlation between ChREBP and TNFα, IL-1β, or IL-6 ([Figure 2](#F2){ref-type="fig"}A--C).

![Expression of serum ChREBP and pro-inflammatory cytokines in T2DM patients\
ELISA was performed to detect the production of inflammatory cytokines including TNFα (**A**), IL-1β (**B**) and IL-6 (**C**), and ChREBP (**D**);\*\**P*\<0.01.](bsr-38-bsr20180767-g1){#F1}

![Correlation between ChREBP and pro-inflammatory cytokines\
Correlation analysis between ChREBP and TNFα (**A**), IL-1β (**B**), and IL-6 (**C**).](bsr-38-bsr20180767-g2){#F2}

ChREBP were increased in diabetic mice and mesangial cells {#sec3-3}
----------------------------------------------------------

C57BL/6 mice with diabetic models were induced by administration with streptozotocin (STZ). Consequently, we found that the mRNA and protein levels of ChREBP were significantly elevated in the kidneys of diabetic mice ([Figure 3](#F3){ref-type="fig"}A,B). Moreover, mRNA expression of its target genes, L-PK, FASN and SCD-1, were also up-regulated ([Figure 3](#F3){ref-type="fig"}C). In addition, we detected the expression of ChREBP and its target genes in mesangial cells response to glucose. As expected, we found that high glucose treatment led to an elevated expression of ChREBP and its target genes, L-PK, FASN and SCD-1, in mesangial cells ([Figure 4](#F4){ref-type="fig"}A--C). Taken together, these results suggested that ChREBP were increased in diabetic mice and glucose-treated mesangial cells.

![Expression of ChREBP and its target genes in diabetic mice\
Real-time PCR and Western blot were performed to determine the mRNA and protein levels of ChREBP (**A** and **B**). The mRNA expression of L-PK, FASN and SCD-1 were measured by real-time PCR (**C**); \*\**P*\<0.01, \*\*\**P*\<0.001.](bsr-38-bsr20180767-g3){#F3}

![Expression of ChREBP and its target genes in mesangial cells response to glucose\
SV40 MES 13 cells were treated with 5 and 25 mM glucose for 48 h, and the levels of ChREBP were measured by real-time PCR (**A**) and Western blot (**B**). In addition, the expression levels of L-PK, FASN and SCD-1 in mesangial cells were measured by real-time PCR (**C**); \*\*\**P*\<0.001.](bsr-38-bsr20180767-g4){#F4}

High glucose induced pro-inflammatory cytokines and apoptosis in mesangial cells {#sec3-4}
--------------------------------------------------------------------------------

To confirm the inflammatory reaction to the high glucose in mesangial cells, we detected the expression of several pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in SV40 MES 13 cells. Results showed that glucose treatment promoted mRNA levels of TNF-α, IL-1β, and IL-6 ([Figure 5](#F5){ref-type="fig"}A). Moreover, flow cytometry analysis showed that glucose stimulation induced significant apoptosis of SV40 MES 13 cells ([Figure 5](#F5){ref-type="fig"}B).

![High glucose induced pro-inflammatory cytokines and apoptosis in mesangial cells\
(**A**) SV40 MES 13 cells were treated with 5, 15, and 50 mM glucose for 48 h, the levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6) were determined by ELISA. (**B**) SV40 MES 13 cells were treated with 0, 5, 15, and 50 mM glucose for 48 h, cells were harvested and cell apoptosis ratio was analyzed by flow cytometry.](bsr-38-bsr20180767-g5){#F5}

ChREBP mediated inflammatory reactions in mesangial cells induced by glucose administration {#sec3-5}
-------------------------------------------------------------------------------------------

To explore the role of ChREBP in the inflammatory response, we manipulated the ChREBP level in mesangial cells using RNAi method. We found that transfection with ChREBP siRNA significantly inhibited the mRNA and protein expression of ChREBP in SV40 MES 13 cells ([Figure 6](#F6){ref-type="fig"}A,B). As a result, the expression levels of TNF-α ([Figure 6](#F6){ref-type="fig"}C), IL-1β ([Figure 6](#F6){ref-type="fig"}D), and IL-6 ([Figure 6](#F6){ref-type="fig"}E) were also significantly reduced in mesangial cells after transfection with ChREBP siRNA.

![ChREBP mediated inflammatory reactions in mesangial cells induced by glucose administration\
SV40 MES 13 cells were transfected with control siRNA or siRNA against ChREBP for 48 h, the mRNA (**A**) and protein (**B**) levels of ChREBP were determined by real-time PCR and Western blot assay, respectively. SV40 MES 13 cells were transfected with control siRNA or siRNA against ChREBP for 24 h and treated with 5, 15, and 50 mM glucose for additional 48 h, the levels of inflammatory cytokines including TNF-α (**C**), IL-1β (**D**), and IL-6 (**E**) were determined by ELISA; \*\**P*\<0.01, \*\*\**P*\<0.001.](bsr-38-bsr20180767-g6){#F6}

Discussion {#sec4}
==========

ChREBP is a critical transcription factor that primarily mediates glucose homeostasis \[[@B10]\]. Recently, a study investigated the role of ChREBP in mesangial cells in DN. They found that treatment with high glucose increased cellular O-GlcNAc and O-GlcNAcylated ChREBP in mesangial cells, which in turn augmented the protein stability, transcriptional activity, and nuclear translocation of ChREBP \[[@B11],[@B12]\]. In the present study, we observed the elevated expression of ChREBP in T2DM patients, high glucose-treated mesangial cells, and diabetic mice. Additionally, the target genes of ChREBP, L-PK, FASN, and SCD-1 were also up-regulated. Therefore, these results demonstrate that ChREBP might play a critical role in the development of DN.

It is widely considered that DN is a chronic low-grade inflammatory disease \[[@B13]\]. Many inflammatory cytokines are shown to be involved in the pathogenesis and clinical outcome of DN, such as TNF-α, IL-1β, and IL-6 \[[@B16]\]. Therefore, targeting cytokine production many be an effective therapeutic strategy against DN. Actually, the administration of anti-inflammatory activities is able to reduce the renal dysfunction and damage induced by DN \[[@B19]\]. In our study, the serum levels of TNFα, IL-1β, and IL-6 were up-regulated in T2DM patients and mesangial cells. In addition, there was a positive correlation between ChREBP and TNFα, IL-1β, or IL-6. High glucose administration can increase the generation of ROS, which correlates with ATP production and apoptosis in mesangial cells \[[@B20]\]. Consistently, we observed that glucose stimulation induced significant apoptosis of SV40 MES 13 cells. To further confirm the role of ChREBP in inflammatory responses, we manipulated the ChREBP level in mesangial cells using RNAi method. Consequently, down-regulation of ChREBP suppressed the expression levels of TNF-α, IL-1β, and IL-6 in SV40 MES 13 cells.

There are several limitations of this study. First, we detected the expression of ChREBP in a relatively small sample size, which should be further validated in a larger cohort population. Second, the knockdown of ChREBP was only performed in renal mesangial cells, and thus the *in vivo* data of depletion of ChREBP were absent. In our future study, we will knockdown ChREBP to validate its role in the rat DN model. At last, the specific underlying mechanism by which ChREBP exerts its biological role in diabetes is not fully elucidated.

In summary, the present study reveals that ChREBP is elevated by the glucose *in vivo* or *in vitro*, in an association with an elevated inflammatory response. Moreover, the strategy of ChREBP inhibition reduced the inflammatory cytokines in response to high glucose. The present study demonstrates that ChREBP may be developed as a novel therapeutic target for controlling the progression of DN.
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